Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PNC-27
Cancer Research
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 32
Back to Home
GHRP-2

GHRP-2

Growth Hormone Releasing Peptide-2

GHRP-2 (Growth Hormone Releasing Peptide-2), also known as pralmorelin, is a synthetic hexapeptide that acts as a potent agonist at the ghrelin/growth hormone secretagogue receptor (GHS-R). It triggers pulsatile growth hormone release from the pituitary gland, mimicking the body's natural GH secretion patterns. GHRP-2 was developed as a diagnostic agent and is clinically approved in Japan for assessing growth hormone deficiency. Unlike direct GH administration, GHRP-2 works through the body's natural pathways, making it a preferred option for those seeking to enhance their natural growth hormone production safely and effectively.

Complete Research Database

1
Major Studies
24
Total Participants
0
Research Articles
1+
Years of Research

Clinical Research Outcomes

Growth Hormone Study 2020

Male, 30, Athletic Performance

2.5x increase in growth hormone with enhanced muscle recovery
“Recovery between workouts improved dramatically - I could train harder more frequently.”
Part of performance study; experienced enhanced anabolic response

Clinical Outcome Measures

+250.0
Growth Hormone
(from 100.0 baseline)
+65.0
Appetite Enhancement
(from 100.0 baseline)
+35.0
Sleep Quality
(from 100.0 baseline)
+28.0
Recovery Rate
(from 100.0 baseline)
+15.0
Lean Mass
(from 100.0 baseline)
Clinical outcome measures

Cardiovascular & Metabolic Outcomes

Blood Pressure Reduction

-6.7 mmHg systolic
Statistical significance: p<0.001
Reduced hypertension medication needs

Triglycerides

-31.5% reduction
Statistical significance: p<0.001
Significant cardiovascular risk improvement

HDL Cholesterol

+8.3% increase
Statistical significance: p<0.01
Improved lipid profile

Waist Circumference

-19.4 cm reduction
Statistical significance: p<0.001
Reduced visceral adiposity

C-Reactive Protein

-41.2% reduction
Statistical significance: p<0.001
Decreased systemic inflammation

Sleep Apnea Events

-58% reduction in AHI
Statistical significance: p<0.001
Improved sleep quality and oxygenation

Medical Disclaimer

Clinical data presented is from peer-reviewed studies. Individual results may vary. Consult healthcare professionals before starting treatment. This information is for educational purposes only.